Best of the Week
Most Popular
1. Gold vs Cash in a Financial Crisis - Richard_Mills
2.Current Stock Market Rally Similarities To 1999 - Chris_Vermeulen
3.America See You On The Dark Side Of The Moon - Part2 - James_Quinn
4.Stock Market Trend Forecast Outlook for 2020 - Nadeem_Walayat
5.Who Said Stock Market Traders and Investor are Emotional Right Now? - Chris_Vermeulen
6.Gold Upswing and Lessons from Gold Tops - P_Radomski_CFA
7.Economic Tribulation is Coming, and Here is Why - Michael_Pento
8.What to Expect in Our Next Recession/Depression? - Raymond_Matison
9.The Fed Celebrates While Americans Drown in Financial Despair - John_Mauldin
10.Hi-yo Silver Away! - Richard_Mills
Last 7 days
PAYPAL WARNING - Your Stimulus Funds Are at Risk of Being Frozen for 6 Months! - 5th Apr 20
Stocks Hanging By the Fingernails? - 5th Apr 20
US Federal Budget Deficits: To $30 Trillion and Beyond - 5th Apr 20
The Lucrative Profitability Of A Move To Negative Interest Rates - Pandemic Edition - 5th Apr 20
Visa Denials: How to avoid it and what to do if your Visa is denied? - 5th Apr 20 - Uday Tank
WARNING PAYPAL Making a Grab for US $1200 Stimulus Payments - 4th Apr 20
US COVID-19 Death Toll Higher Than China’s Now. Will Gold Rally? - 4th Apr 20
Concerned That Asia Could Blow A Hole In Future Economic Recovery - 4th Apr 20
Bracing for Europe’s Coronavirus Contractionand Debt Crisis - 4th Apr 20
Stocks: When Grass Looks Greener on the Other Side of the ... Pond - 3rd Apr 20
How the C-Factor Could Decimate 2020 Global Gold and Silver Production - 3rd Apr 20
US Between Scylla and Charybdis Covid-19 - 3rd Apr 20
Covid19 What's Your Risk of Death Analysis by Age, Gender, Comorbidities and BMI - 3rd Apr 20
US Coronavirus Infections & Deaths Trend Trajectory - How Bad Will it Get? - 2nd Apr 20
Silver Looks Bearish Short to Medium Term - 2nd Apr 20
Mickey Fulp: 'Never Let a Good Crisis Go to Waste' - 2nd Apr 20
Stock Market Selloff Structure Explained – Fibonacci On Deck - 2nd Apr 20
COVID-19 FINANCIAL LOCKDOWN: Can PAYPAL Be Trusted to Handle US $1200 Stimulus Payments? - 2nd Apr 20
Day in the Life of Coronavirus LOCKDOWN - Sheffield, UK - 2nd Apr 20
UK Coronavirus Infections and Deaths Trend Trajectory - Deviation Against Forecast - 1st Apr 20
Huge Unemployment Is Coming. Will It Push Gold Prices Up? - 1st Apr 20
Gold Powerful 2008 Lessons That Apply Today - 1st Apr 20
US Coronavirus Infections and Deaths Projections Trend Forecast - Video - 1st Apr 20
From Global Virus Acceleration to Global Debt Explosion - 1st Apr 20
UK Supermarkets Coronavirus Panic Buying Before Lock Down - Tesco Empty Shelves - 1st Apr 20
Gold From a Failed Breakout to a Failed Breakdown - 1st Apr 20
P FOR PANDEMIC - 1st Apr 20
The Past Stock Market Week Was More Important Than You May Understand - 31st Mar 20
Coronavirus - No, You Do Not Hear the Fat Lady Warming Up - 31st Mar 20
Life, Religions, Business, Globalization & Information Technology In The Post-Corona Pandemics Age - 31st Mar 20
Three Charts Every Stock Market Trader and Investor Must See - 31st Mar 20
Coronavirus Stocks Bear Market Trend Forecast - Video - 31st Mar 20
Coronavirus Dow Stocks Bear Market Into End April 2020 Trend Forecast - 31st Mar 20
Is it better to have a loan or credit card debt when applying for a mortgage? - 31st Mar 20
US and UK Coronavirus Trend Trajectories vs Bear Market and AI Stocks Sector - 30th Mar 20
Are Gold and Silver Mirroring 1999 to 2011 Again? - 30th Mar 20
Stock Market Next Cycle Low 7th April - 30th Mar 20
United States Coronavirus Infections and Deaths Trend Forecasts Into End April 2020 - 29th Mar 20
Some Positives in a Virus Wracked World - 29th Mar 20
Expert Tips to Save on Your Business’s Office Supply Purchases - 29th Mar 20
An Investment in Life - 29th Mar 20
Sheffield Coronavirus Pandemic Infections and Deaths Forecast - 29th Mar 20
UK Coronavirus Infections and Deaths Projections Trend Forecast - Video - 28th Mar 20
The Great Coronavirus Depression - Things Are Going to Change. Here’s What We Should Do - 28th Mar 20
One of the Biggest Stock Market Short Covering Rallies in History May Be Imminent - 28th Mar 20
The Fed, the Coronavirus and Investing - 28th Mar 20
Women’s Fashion Trends in the UK this 2020 - 28th Mar 20
The Last Minsky Financial Snowflake Has Fallen – What Now? - 28th Mar 20
UK Coronavirus Infections and Deaths Projections Trend Forecast Into End April 2020 - 28th Mar 20
DJIA Coronavirus Stock Market Technical Trend Analysis - 27th Mar 20
US and UK Case Fatality Rate Forecast for End April 2020 - 27th Mar 20
US Stock Market Upswing Meets Employment Data - 27th Mar 20
Will the Fed Going Nuclear Help the Economy and Gold? - 27th Mar 20
What you need to know about the impact of inflation - 27th Mar 20
CoronaVirus Herd Immunity, Flattening the Curve and Case Fatality Rate Analysis - 27th Mar 20
NHS Hospitals Before Coronavirus Tsunami Hits (Sheffield), STAY INDOORS FINAL WARNING! - 27th Mar 20
CoronaVirus Curve, Stock Market Crash, and Mortgage Massacre - 27th Mar 20
Finding an Expert Car Accident Lawyer - 27th Mar 20
We Are Facing a Depression, Not a Recession - 26th Mar 20
US Housing Real Estate Market Concern - 26th Mar 20
Covid-19 Pandemic Affecting Bitcoin - 26th Mar 20
Italy Coronavirus Case Fataility Rate and Infections Trend Analysis - 26th Mar 20
Why Is Online Gambling Becoming More Popular? - 26th Mar 20
Dark Pools of Capital Profiting from Coronavirus Stock Markets CRASH! - 26th Mar 20
CoronaVirus Herd Immunity and Flattening the Curve - 25th Mar 20
Coronavirus Lesson #1 for Investors: Beware Predictions of Stock Market Bottoms - 25th Mar 20
CoronaVirus Stock Market Trend Implications - 25th Mar 20
Pandemonium in Precious Metals Market as Fear Gives Way to Command Economy - 25th Mar 20
Pandemics and Gold - 25th Mar 20
UK Coronavirus Hotspots - Cities with Highest Risks of Getting Infected - 25th Mar 20
WARNING US Coronavirus Infections and Deaths Going Ballistic! - 24th Mar 20
Coronavirus Crisis - Weeks Where Decades Happen - 24th Mar 20
Industry Trends: Online Casinos & Online Slots Game Market Analysis - 24th Mar 20
Five Amazingly High-Tech Products Just on the Market that You Should Check Out - 24th Mar 20
UK Coronavirus WARNING - Infections Trend Trajectory Worse than Italy - 24th Mar 20
Rick Rule: 'A Different Phrase for Stocks Bear Market Is Sale' - 24th Mar 20
Stock Market Minor Cycle Bounce - 24th Mar 20
Gold’s century - While stocks dominated headlines, gold quietly performed - 24th Mar 20
Big Tech Is Now On The Offensive Against The Coronavirus - 24th Mar 20
Socialism at Its Finest after Fed’s Bazooka Fails - 24th Mar 20
Dark Pools of Capital Profiting from Coronavirus Stock and Financial Markets CRASH! - 23rd Mar 20
Will Trump’s Free Cash Help the Economy and Gold Market? - 23rd Mar 20
Coronavirus Clarifies Priorities - 23rd Mar 20
Could the Coronavirus Cause the Next ‘Arab Spring’? - 23rd Mar 20
Concerned About The US Real Estate Market? Us Too! - 23rd Mar 20
Gold Stocks Peak Bleak? - 22nd Mar 20

Market Oracle FREE Newsletter

Coronavirus-bear-market-2020-analysis

The Ebola Outbreak: U.S. Sponsored Bioterror Weapon?

Politics / Conspiracy Theory Aug 24, 2014 - 06:17 PM GMT

By: Global_Research

Politics

We can now be extraordinarily confident that the U.S. government is lying, in key material respects, about the latest Ebola outbreak—and not just because it lies about nearly everything of political consequence. This article shows that there are compelling reasons to believe we are being told three big lies about Ebola. It also offers a simple, rational, yet disturbing, explanation that very tidily accounts for all three lies. The explanation supposes that the current Ebola outbreak consists in an act of U.S.-linked bioterror.


One key U.S. driven lie has to do with the Western MSM’s insistence that nobody of any repute believes that Ebola might be airborne. On this issue, the Public Health Agency of Canada remarks:

In the laboratory, infection through small-particle aerosols has been demonstrated in primates, and airborne spread among humans is strongly suspected, although it has not yet been conclusively demonstrated (1, 6, 13). The importance of this route of transmission is not clear. Poor hygienic conditions can aid the spread of the virus.

A few scientific studies expressing concern about the airborne possibility are cited in this article, and other such studies are not hard to find.

So there are people with authority to speak to the issue who believe that there is some cause for concern regarding the airborne Ebola prospect, but the U.S. government/MSM complex instead lies and acts like this isn’t the case.

Before getting to the second U.S. lie, it is important to mention three facts that have not received enough discussion. First—and this may be of pivotal significance–we still have no ideahow Ebolagot to West Africa. See for yourself; there’s never been an Ebola outbreak in West Africa before.

Perhaps the racist U.S./MSM view is that all African countries are the same, so who cares?

Second, the current outbreak, in terms of the number and international breadth of infections, does seem to be far more contagious than any previous outbreak; as the previous link shows, we now have at least 1,975 cases.

Now pause for a moment and take this fully on board: the 1,975 cases exceed the total number of Ebola cases from 1977 to 2014’s outbreak. So it’s no surprise that we have, for example, signs of infected individuals in Albania.

The second lie really is a lie of nondisclosure, and concerns the reality that the MSM has not told us that we are dealing with a biologically distinct form of Ebola that has never been seen before.

So, consider the following disconcerting information appearing in the New England Journal of Medicine in April 2014 regarding the current West African, Guinean outbreak of Ebola:

Phylogenetic analysis of the full-length sequences established a separate clade for the Guinean EBOV strain in sister relationship with other known EBOV strains. This suggests that the EBOV strain from Guinea has evolved in parallel with the strains from the Democratic Republic of Congo and Gabon from a recent ancestor and has not been introduced from the latter countries into Guinea. Potential reservoirs of EBOV, fruit bats of the species Hypsignathusmonstrosus, Epomopsfranqueti, & Myonycteristorquata, are present in large parts of West Africa.18 It is possible that EBOV has circulated undetected in this region for some time. The emergence of the virus in Guinea highlights the risk of EBOV outbreaks in the whole West African subregion.

Furthermore, from the same study:

The high degree of similarity among the 15 partial L gene sequences, along with the three full-length sequences and the epidemiologic links between the cases, suggest a single introduction of the virus into the human population. This introduction seems to have happened in early December 2013 or even before.

So, the Guinean variant of Ebola we now confront has been found to be sufficiently genetically distinct from all previous versions of Ebola that it has been assigned its own genetic branch, or clade, and it is believed to have evolved in parallel from an ancestor held in common with a variant of Ebola native to the Democratic Republic of Congo and Gabon. Moreover, the current outbreak began not in June or July, but as early as April 2014 and perhaps even earlier than December, 2013.

And, we seem to have a single introduction of the Guinea (West African) Ebola variant into the human population. Thus, we seem not to have, for example, something along the lines of multiple bites of humans by supposedly Guinea variant Ebola infected fruit bats.

Finally, the Western Africa Ebola outbreak does not appear to be traceable to Central Africa or anywhere else, and so we still do not know how Ebola got to West Africa.

Let us briefly summarize before presenting the third U.S. Ebola lie and concluding with a reasonable explanation that ties the three lies together.

The Guinea Ebola variant has never been seen before. It might well be far more contagious than any Ebola variant hitherto encountered; it could even be airborne. We still have no idea how Ebola arose in West Africa, but it did so some time ago—well before the Western MSM started to spew its lies.

Now the third U.S. Ebola lie: In a Matt Drudge-linked article entitled “The Federal Government’s Inconsistent Ebola Story”, we find that the U.S. government is telling two completely inconsistent stories regarding the circumstances surrounding delivery of MappPharmaceuticals’ magic ZMapp Ebola drug to Dr. Kent Brantly and Nancy Writebol. Thus, we have:

According to the CDC, it was Samaritan’s Purse, the private humanitarian organization that employs Dr. Brantley, who reached out to them in an attempt to find an experimental Ebola drug. The CDC says it passed Samaritan’s Purse along to NIH, who referred them to contacts within Mapp.

“This experimental treatment was arranged privately by Samaritan’s Purse,” the CDC said. “Samaritan’s Purse contacted the Centers for Disease Control and Prevention (CDC), who referred them to the National Institutes of Health (NIH). NIH was able to provide the organization with the appropriate contacts at the private company developing this treatment. The NIH was not involved with procuring, transporting, approving, or administering the experimental treatments.”

The New York Times first reported this version of events on Aug. 6, and the statement was posted on the CDC’s website a few days later,where it remains.

But, as the Morning Consult reports in the same article, we also have:

But the NIH told Morning Consult one of its scientists on the ground in West Africa approached the charity before the group had even decided to pursue an experimental alternative.

“The NIH scientist who was in West Africa referred Samaritan’s Purse to company contacts because they were best equipped to answer questions about the status of their experimental treatment,” the agency said in an email to Morning Consult. “This occurred before Samaritan’s Purse decided to pursue an experimental therapy.”

A statement from Samaritan’s Purse also conflicts with the CDC’s telling of events, and indicates the NIH and other government agencies may have played an active role in procuring the drugs.

“The experimental medication given to Dr. Brantley was recommended to us,” the group said. “We didn’t seek it out, but worked with the National Institutes of Health and other government agencies to obtain this medication.”

Hence, we have the U.S. government saying both that delivery of the drug to the aid workers was initially government’s idea, and that it wasn’t initially government’s idea. Since both of these possibilities cannot be true, we have our third U.S. federal Ebola lie.

But whose idea was it, really, to deliver the ZMapp magic serum (which is said to have begun reversing Brantly’s condition within 20 minutes to an hour)? In all likelihood it was the U.S. government’s idea, at a minimum for the following reason mentioned in the Morning Consult article:

If [Mapp] did this on their own, they must have had unbelievable confidence in the product and lawyers who know this up and down,” Vox said. “If they went this alone, their investors should be worried, because that’s reckless. A team of scientists could get in a lot of trouble doing that, and I can’t imagine they run their company that way, especially considering they have support from the Department of Defense.

Let’s put all of the above together and move toward wrapping matters up.We have what appears to be the most contagious variant of Ebola ever encountered, its genetic form is novel in important respects, and we still have no idea how it arose in West Africa.

Yet, we are told that an experimental drug, ZMapp—produced by a previously unheard of U.S. firm with U.S. Department of Defense ties—is functioning in miraculous fashion. Furthermore, the U.S. government cannot keep its story straight about who initiated the delivery of the experimental drug to the U.S. aid workers, but there are compelling reasons to suppose it was the U.S. government that engineered the delivery.

All of the foregoing should prompt us to ask: When was Mapp Pharmaceutical’s magic drug ZMappdeveloped?

The following language, drawn from an article at International Business Times, might provide guidance:

A statement from Mapp said:

“ZMapp is the result of a collaboration between Mapp Biopharmaceutical Inc, LeafBio, DefyrusInc, the US government and Public Health Agency of Canada.

“ZMapp is composed of three ‘humanised’ monoclonal antibodies manufactured in plants, specifically Nicotiana. It is an optimised cocktail combining the best components of MB-003 and ZMAb.

“ZMapp was first identified as a drug candidate in January 2014 and has not yet been evaluated for safety in humans. As such, very little of the drug is currently available. Any decision to use an experimental drug in a patient would be a decision made by the treating physician under the regulatory guidelines of the FDA.

One very interesting thing to note is the parties involved in producing ZMapp. Two of the parties are the U.S. government and the Public Health Agency of Canada—and the Public Health Agency of Canada, you will recall, is the very same agency that “strongly suspects” that Ebola might be airborne (see the second paragraph of this article). Yet, we are constantly told the U.S. government suspects no such thing.

But there are even more important things to consider.

Does “ZMapp was first identified as a drug candidate in January 2014” mean that ZMappwas designed from the ground up, pretty much when the outbreak began, with the specific purpose of treating the Guinea Ebola variant (see above for timing of the outbreak)? Or, does it mean that ZMapp was repurposed in some way to grapple with the Guinea variant? Or does it perhaps mean something else entirely?

In any event, if the above MappPharmaceuticals statement is true, this much is perfectly clear: a major decision about ZMapp and its potential efficacy was made in January 2014, and that decision appears to have been made very close on the heels of the beginning of the current Guinea Ebola outbreak.

Therefore, if ZMapp really is the miraculous success it is purported to be, we are given to believe that, in Research and Development terms, results must have been achieved virtually overnight. This is because with the beginning of the outbreak of the brand newGuinea Ebola variant dated to around December 2013, Mapp could not possibly have had much time before its January 2014 decision to target the Guinea Ebola variant with ZMapp.

Or might Mappin fact have had plenty of time?

One possibility is that Mappdid have plenty of time, because it knew about the brand new Ebola variant before its debut appearance in West Africa. This would be very strong evidence of a bioterror conspiracy, would it not? Of course, we are very far from sure about this prospect.

However, even if we are to believe that Mapp did not know about the novel Guinea Ebola variant before that variant’s first appearance, but did in fact advance anyway with ZMapp againstthe Guinea variant in January 2014, wemust still ask exactly how ZM appended up being effective against a brand new variant Mapp would, under the present assumption, have only just encountered.

Perhaps Mapp had been in the process of designing ZMapp so that it could successfully attack already extant Ebola variants, and whatever properties made it effective against those already extant variants also transferred to the novel Guinea variant?

Maybe.

But if that is so, ZMapp should prove successful against variants of Ebola other than the Guinea variant. Will it?

If it doesn’t prove successful against variants of Ebola other than the Guinea variant, I do not see how one can logically avoid the conclusion that the West African rooted, Guinea variant of Ebola amounts to U.S. government linked bioterror.

Unless, of course, one is willing to invoke what amounts to a miraculous stroke of luck consisting in the design of a solution that successfully attacks something that’s never been seen before and was not anticipated—even though the solution fails against related versions of the same problem.

In closing, please note that the U.S. act of bioterror explanation economically accounts for all three U.S. lies discussed in the article. It explains why the U.S. government is lying about the airborne status of Ebola, why the U.S. government/MSM hybrid is in no hurry to disclose the geographical and virological novelties of the Guinea variant, and, finally, why the U.S. government, out of one side of its mouth, wants to act like its “miracle experimental drug” had to be pried out of its greedy and comprehensive regulatory hands.

It must be stated, though, that there is one last possibility after all, which is that the Dr. Kent Brantly miracle recovery is no real recovery at all.

Dr. Jason Kissner is Associate Professor of Criminology at California State University. Dr. Kissner’s research on gangs and self-control has appeared in academic journals. His current empirical research interests include active shootings. You can reach him atcrimprof2010@hotmail.com

Global Research Articles by Jason Kissner

© Copyright Dr. Jason Kissner, Global Research, 2014

Disclaimer: The views expressed in this article are the sole responsibility of the author and do not necessarily reflect those of the Centre for Research on Globalization. The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible or liable for any inaccurate or incorrect statements contained in this article.


© 2005-2019 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in

6 Critical Money Making Rules